非小细胞肺癌EGFR-TKI耐药与 p53 基因突变的研究进展

打开文本图片集

中图分类号：R734.2 文献标志码：A DOI：10.11958/20252986

Abstract：Themainreason forthefailure of epidermal growthfactorreceptor tyrosine kinase inhibitors （EGFR-TKIs） inthe treatmentofnon-smallcellungcancer（NSCLC）is targeting drug resistance，andthe maincauseofdrug resistanceis the mutation of the tumor suppressor gene p53 .How to prevent or reverse p53 mutations to solve the problem of EGFR-TKI resistance inadvanced NSCLC has becomearesearch hotspot inthis field.This article summarizes thecommon mutation types of p53 and their related mechanisms affecting EGFR-TKI resistance，as well as how to intervene in p53 mutations to reverse EGFR-TKIresistance，andconducts an in-depth discussionon therelationshipbetween EGFR-TKIresistanceand p53 mutations in NSCLC patients.

Key Words： carcinoma， non-small-cell lung; genes， p53;mutation; EGFR-TKI

非小细胞肺癌（NSCLC）是肺癌中最常见的类型，中国每年新增NSCLC患者70.4万例，因NSCLC死亡约55.8万[1-2]。（剩余12542字）